Caris Life Sciences, Inc. (CAI)
NASDAQ: CAI · Real-Time Price · USD
18.44
-1.49 (-7.48%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Caris Life Sciences Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Market Capitalization | 5,212 | 7,612 | - | - | - |
| Enterprise Value | 4,841 | 7,284 | - | - | - |
| Last Close Price | 18.44 | 26.98 | - | - | - |
| PS Ratio | 6.42 | 9.37 | - | - | - |
| PB Ratio | 9.02 | 13.19 | - | - | - |
| P/TBV Ratio | 9.34 | 13.64 | - | - | - |
| P/FCF Ratio | 77.92 | 113.80 | - | - | - |
| P/OCF Ratio | 62.68 | 91.54 | - | - | - |
| EV/Sales Ratio | 5.96 | 8.97 | - | - | - |
| EV/EBITDA Ratio | 71.48 | 107.54 | - | - | - |
| EV/EBIT Ratio | 107.32 | 161.45 | - | - | - |
| EV/FCF Ratio | 72.37 | 108.88 | - | - | - |
| Debt / Equity Ratio | 0.74 | 0.74 | -1.53 | -11.04 | 1.08 |
| Debt / EBITDA Ratio | 5.45 | 5.45 | - | - | - |
| Debt / FCF Ratio | 6.39 | 6.39 | - | - | - |
| Net Debt / Equity Ratio | -0.64 | -0.64 | -1.29 | -4.86 | -0.55 |
| Net Debt / EBITDA Ratio | -5.48 | -5.48 | -1.72 | -0.35 | 0.52 |
| Net Debt / FCF Ratio | -5.54 | -5.54 | -1.41 | -0.32 | 0.42 |
| Asset Turnover | 1.11 | 1.11 | 1.09 | 0.54 | - |
| Inventory Turnover | 5.25 | 5.25 | 5.24 | 4.48 | - |
| Quick Ratio | 7.16 | 7.16 | 0.93 | 1.86 | 3.29 |
| Current Ratio | 7.85 | 7.85 | 1.30 | 2.55 | 3.77 |
| Return on Equity (ROE) | -45.37% | -45.37% | - | -293.82% | - |
| Return on Assets (ROA) | 3.84% | 3.84% | -42.48% | -35.34% | - |
| Return on Capital Employed (ROCE) | 4.50% | 4.50% | -144.20% | -100.60% | -54.40% |
| Earnings Yield | -10.32% | -0.89% | - | - | - |
| FCF Yield | 1.28% | 0.88% | - | - | - |
| Buyback Yield / Dilution | -371.04% | -371.04% | -1.59% | -4.73% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.